Outliving Cancer: Recent Episodes
Dr. Robert Nagourney
“Outliving Cancer” brings a new perspective to the treatment of human malignancy. Drawing upon years of experience, Dr. Robert Nagourney, Medical oncologist and Laboratory scientist brings his unique insights into the diagnosis, causes and treatments of this disease. Join Dr. Nagourney as he explores the cellular origins of human cancer and examines better ways to use existing drugs, targeted agents and a growing number of novel combinations to successfully confront a disease that today is the 2nd leading cause of death in America. It is Dr. Nagourney’s intent to provide cancer patients with the tools that they will need to “outlive their cancers”.
Dr. Nagourney offers a fundamental discussion of the concept of human metabolism on today’s episode of Outliving Cancer.
Today on Outliving Cancer, Dr. Nagourney discusses the metabolic basis of human malignancy -- the history, present and future -- and new groundbreaking studies.
Today on Outliving Cancer, Dr. Nagourney introduces colleague and research collaborator Dr. Paulo D’Amora on using quantitative Mass Spectrometry in identifying metabolic signatures to determine a predisposition to disease.
Dr. Nagourney discusses on today’s episode a recent study he and colleagues conducted that was able to identify gynecologic cancer patients at the highest risk of relapse. The results could herald a future in which oncologists could use a blood test done at the time of diagnosis to better manage patients with advanced gynecologic malignancies.
Today Dr. Robert Nagourney discusses treatment options for Triple Negative Breast Cancer, which accounts for 10 to 15 percent of all breast cancers and tends to grow and spread faster than other breast cancers.
Dr. Robert Nagourney today discusses an important presentation conducted at an American Association for Cancer Research Special Conference on Pancreatic Cancer.
Today Dr. Nagourney discusses the management of breast cancer, specifically HER2-positive breast cancer, and visits with a patient who has a remarkable story and shares her experience.
Dr. Nagourney discusses this week the issues that doctors can face when trying to help patients as they come against sometimes strict and rigid dictates in process protocols that are not always in the patient’s best interest.
Dr. Nagourney looks back in time at cancer research and then looks ahead at the potentials of treatment. He reviews the process of cell death in cancer and the potential of predictive outcomes in cancer therapy.
Dr. Nagourney reviews cancer and asks the question: What are we dealing with in cancer, and how to confront it as if going to war. Why do patients who don’t get cured become progressively more resistant to therapy?
Pancreatic cancer is one of the most challenging of all cancers. Early diagnosis for pancreatic cancer is difficult, and as a result, most people are diagnosed with later stage pancreatic cancer, which has very low survival rates. Today, however, Dr. Nagourney discusses the opportunities that exist in treating this cancer, and welcomes as his guest Steven Lockwood, who he has treated for pancreatic cancer.
Today on Outliving Cancer, Dr. Nagourney Dr. Nagourney discusses the topic of targeted therapy, the concepts, how it’s practiced, and the approach in cancer medicine.
In the previous episode, Dr. Nagourney discussed targeted cancer therapy. One particular class of targeted agents are called epidermal growth factors. The epidermal growth factor receptor protein is involved in cell signaling pathways that control cell division and survival. Drugs that block epidermal growth factor receptor proteins can be used for certain kinds of cancer.
Dr. Nagourney today discusses how cancer is a clonal disease, and how that impacts potential treatm
Vitamin C truly may be an excellent option for fighting cancer. It is increasingly evident that Vitamin C, known for its antioxidant properties, can also function as a “pro-oxidant”. Pro-oxidants introduce higher levels of toxic free radicals into their surroundings which can cause both harm and therapeutic benefit.
Dr. Nagourney turns detective today as he deciphers and ultimately exposes the herbal treatment PC-SPES for prostate cancer as non-herbal. But he has not given up that some herbal agents may be helpful in cancer treatment and prevention.
Dr. Nagourney today examines the options for bladder cancer and the potential for a new class of drugs.
Dr. Nagourney discusses thedevelopment of drug resistance in colon cancer patients that contributed to the failure of the oxaliplatin-based HIPEC PRODIGE 7 Trial
Dr Nagourney looks at the amazing impact foods such as garlic can have on cancer. Garlic contains more than a dozen active chemical substances, many of which have been shown to have antiviral, antibacterial, blood pressure and cholesterol lowering, as well as anti-cancer benefits.
Dr. Nagourney discusses treatment of pancreatic cancer and options while interviewing a patient with cancer of the pancreas.
Today Dr. Nagourney examines this year’s American Society of Clinical Oncology annual meeting and some significant breakthroughs in immunotherapy.
In the study of human metabolism, Dr Nagourney today discusses the metabolic abnormalities that lead to breast cancer.
In 2021, we will have 1.9 million new diagnosis of cancer and 600,000 deaths in the U.S. alone. Today Dr. Nagourney will be discussing how cancer comes from alterations in metabolism.
Dr. Nagourney today discusses that just because a cancer drug works, it does not answer why it works.
Dr. Nagourney discusses how, in January of 1985, while a fellow at Scripps Clinic in La Jolla, California, he conducted the original laboratory experiments that tested 2-CdA against hairy cell leukemia, showing for the first time that this drug was highly active in this disease.
Dr. Nagourney examines the very latest from the American Association for Cancer Research in 2021.
Tom Stockwell, whose son passed away from a rare cancer shortly after being diagnosed at age 18, has focused on helping others find personalized treatment and ultimately, hopefully, a cure. On today’s episode, Dr. Nagourney talks with Tom.
Some cancers are so uncommon, that we have to approach treatments with very little data and with very little literature. Functional profiling can help target these rare cancers.
Dr. Nagourney asks the big question: How do oncologists choose the drugs they use to treat their patients? It may sound simple, but it can be very complex.
Dr. Nagourney continues his discussion on the details of a disease that is so important to millions of Americans as he interviews Maria Lewis, who overcame advanced cancer several years ago by using functional profiling.
Dr. Nagourney discusses the details of a disease that is so important to millions of Americans as he interviews Maria Lewis, who overcame advanced cancer several years ago by using functional profiling.
Dr. Nagourney highlights several remarkable examples of results for patients of advanced years in this episode of Outliving Cancer.
The influence of age on cancer therapy. Dr. Nagourney examines the process of aging and its impact on cancer care.
Dr. Nagourney discusses how human tumor biology is evolutionary. If we consider how cancers adapt to micro-environmental stressors, many of which we call therapies, we see the process of evolution accelerated as cancer cells divide. By condensing evolutionary adaptation, cancers can outdo our best therapies.
Dr. Nagourney examines the important distinction between gene tests and functional tests. It is critically important that all patients understand this fundamental distinction if they are to use functional profiling to gain the upper hand in their cancer management.
The conventional wisdom in cancer treatment and research is that More is Better. Dr. Nagourney explains that it not “how much” of a drug you receive, but instead “what” drug you receive that determines outcome.
Dr. Nagourney discusses how drugs gain FDA approval and go on to clinical application but fail to realize their full potential as rigid guidelines undermine the intelligent use of active treatments and combinations.
Cancer patients today confront a dizzying array of treatment options but current “protocol-driven” therapies have had little impact on survival. Patients need actionable information and Dr. Nagourney provides just that.
Dr. Nagourney addresses the fundamental question: “What is cancer?” as he examines the history of cancer research from its earliest origins with the work of Rudolph Virchow in the 1850s to the most modern tenets of contemporary molecular biology.